Valuation: Verastem, Inc.

Market Cap 536M 466M 434M 398M 752M 51.17B 764M 5.11B 2.01B 25.47B 2.01B 1.97B 85.42B P/E 2026 *
-3.85x
P/E 2027 * -5.44x
Enterprise Value 371M 323M 300M 276M 521M 35.42B 529M 3.54B 1.39B 17.63B 1.39B 1.36B 59.13B EV / Sales 2026 *
3.64x
EV / Sales 2027 * 1.83x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-8.44%
1 week-7.26%
Current month+46.87%
1 month+36.84%
3 months-3.93%
6 months-10.23%
Current year-27.33%
1 week 5.58
Extreme 5.585
6.46
1 month 4.07
Extreme 4.07
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-8.44%-7.26%-9.07%-49.27% 536M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-7.38%+25.34%+63.02% 53.75B
-2.41%+1.79%-15.41%-16.48% 23.48B
-4.16%-8.80%-9.10%+341.44% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-1.06%+29.29%-33.32% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-4.55%-3.60%+47.36%+170.80% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average -1.00%-0.91%+30.06%+135.50% 23.4B
Weighted average by Cap. +0.09%+0.10%+27.38%+120.24%

Financials

2026 *2027 *
Net sales 102M 88.56M 82.43M 75.68M 143M 9.72B 145M 972M 381M 4.84B 383M 374M 16.23B 178M 155M 144M 132M 250M 17.03B 254M 1.7B 668M 8.48B 670M 655M 28.42B
Net income -166M -144M -134M -123M -232M -15.8B -236M -1.58B -620M -7.87B -622M -608M -26.38B -142M -123M -115M -106M -199M -13.56B -202M -1.35B -532M -6.75B -534M -522M -22.64B
Net Debt -165M -143M -134M -123M -231M -15.75B -235M -1.57B -618M -7.84B -620M -606M -26.29B -210M -182M -170M -156M -294M -20.01B -299M -2B -785M -9.96B -787M -770M -33.4B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
01/08/26 US$5.595 -8.28% 610,235
30/07/26 US$6.100 +1.50% 1,451,955
29/07/26 US$6.010 -3.53% 2,249,888
28/07/26 US$6.230 +2.47% 1,275,019
27/07/26 US$6.080 +0.50% 2,244,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.100USD
Average target price
15.00USD
Spread / Average Target
+145.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock